CHICAGO, Aug. 8, 2011 /PRNewswire/ -- Zacks Equity Research highlights E.I. DuPont de Nemours & Co. (NYSE: DD) as the Bull of the Day and Tessera Technologies (Nasdaq: TSRA) as the Bear of the Day. In addition, Zacks Equity Research provides analysis Procter & Gamble Co. (NYSE: PG), Kimberly-Clark Corporation (NYSE: KMB) and Johnson & Johnson (NYSE: JNJ).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
E.I. DuPont de Nemours & Co. (NYSE: DD) reported second-quarter earnings of $1.37 per share, surpassing the Zacks Consensus Estimate by $0.04. Revenues reached $10.3 billion, compared with the Zacks Consensus Estimate of $9.95 billion. Earnings benefited from price increases that significantly outpaced higher costs for raw materials and energy.
The company remains vigilant in its focus on productivity with respect to fixed costs, variable costs and working capital, the expectation for continued global economic growth and about $.05 per share full-year operating earnings from Danisco on an underlying basis.
DuPont increased its full-year earnings guidance to between $3.90 and $4.05 from $3.65 to $3.85, due to stronger business results. We remain optimistic on the company and maintain our Outperform recommendation with a target price of $63.00.
Tessera Technologies (Nasdaq: TSRA) is a provider of back-end technology for semiconductor manufacturing. Protection of intellectual property (IP) for a company this small is a challenge, as are the inherent pricing pressures in the DRAM market.
We expect 2011 to see only slight growth and escalated litigation, as customers continue to use the technology without renewing their licenses. The wafer level optics technology will also make a slower start than initially expected.
The company derives a significant percentage of its revenues from the relatively small image sensor market. Management has admitted that the adoption of Tessera's wafer level optics technology was at much slower rates than was originally anticipated, which prompted Tessera to lower revenue targets for 2011.
Latest Posts on the Zacks Analyst Blog:
P&G Ahead of Estimates
Procter & Gamble Co. (NYSE: PG) reported modest results for the fourth quarter of 2011. Net earnings from continuing operations were 84 cents a share, up 18.0% year-over-year, and two pennies above the Zacks Consensus Estimate of 82 cents. Profits were driven by sales growth and operating margin expansion.
Earnings for the full year 2011 went up 11% year over year fuelled by sales growth and a lower effective tax rate to $3.93 per share. The full year earnings matched Zacks Consensus estimate.
Procter & Gamble forecasts first-quarter 2011 net earnings from continuing operations and core earnings to be in the range of $1.00 to $1.04 per share, a decrease of two percent versus an increase of two percent in the corresponding prior-year quarter. The guidance implies that P&G will continue to engage in several innovations and invest in various marketing program. The Zacks Consensus Estimate for the third quarter is expected to be$1.14 per share.
Diluted net earnings per share from continuing operations and Core EPS are expected to be in the range of $4.17 to $4.33, up by 6 to 10 percent (point?). The Zacks Consensus Estimate for fiscal 2011 is $4.28.
Revenue and Margins
P&G's net sales inched up marginally by 10% to $20.9 billion in the fourth-quarter fiscal 2011. Excluding the impact of acquisitions, divestitures and foreign exchange, organic sales grew by 3% in the reported quarter.
For fiscal 2011, net sales increased 5% to $82.6 billion on the back of volume growth of 6%. Excluding the impact of acquisitions, divestitures and foreign exchange, organic sales increased 4% in the year.
For the quarter volume growth was broad-based led by high single-digit growth in Baby Care & Family Care. All geographic regions maintained or grew volume. In the year 2011, unit volume increased in all reportable segments due to investments in innovation and market expansions, such as 'Olay' and 'Head & Shoulders' in Brazil, 'Gillette Guard' in India.
Procter & Gamble, the leading manufacturer and seller of consumer goods, projects net sales and organic sales (based on solid volume momentum, partially offset by product mix and pricing) to inflate 5%–9% and 3%–6%, respectively, in the fiscal year 2011. For first quarter 2012, net sales are expected to grow by 6%–9%. Organic sales are expected to grow two to four percent
Gross margin for the quarter declined 120 basis points primarily attributable to higher commodity costs and unfavorable product mix. For the year, gross margin contracted 140 basis points to 50.6 percent of net sales due to higher commodity costs and unfavorable product mix, partially offset by cost savings on manufacturing.
Operating margin increased 10 basis points (bps) in 4Q11, behind lower selling, general and administrative expenses (SG&A) as a percentage of net sales, partially offset by a lower gross margin. For the full year operating margin sunk by 110 bps due to gross margin contraction, partially offset by lower SG&A as a percentage of net sales.
Other Financial Updates
Procter & Gamble exited the quarter with cash and cash equivalents of $2,768 million and long-term debt of $22,033 million.
We are encouraged by the company's expansion of its portfolio of brands, both through internal development and acquisition. However, Procter and Gamble currently is facing high commodity cost inflation and severe competition from companies like Kimberly-Clark Corporation (NYSE: KMB) and Johnson & Johnson (NYSE: JNJ) in the Western European markets in both the blade and battery businesses.
P&G holds a Zacks #3 Rank, translating into a short-term 'Hold' rating.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=7158.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
Share this article